CTNNB1 and pancreatic neoplasm: Subclonal pathogenic mutations were identified, such as ERBB2 p.S310F (VAF = 3.96%), CTNNB1 p.S45F (3.14%), KRAS p.Q61H (0.86%), ELF3 frameshift (0.55%) and APC frameshift (0.55%) in biliary-pancreatic tumors and TP53 p.E285 (2.01%), PIK3CA p.E545K (1.77% and 1.34%), PIK3CA p.D1029N (0.70%), and HRAS p.G12C (0.53%) in non-small cell lung cancers.